Katsuya Nagaoka

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 16

Top Topics

Hepatitis C Virus

Vascular Endothelial Growth Factor

Top Venues

Hepatology research : the official journal of the Japan Society of Hepatology

Cancer medicine

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Takehisa Watanabe, Katsuya Nagaoka
An RNA-degrading enzyme emerges as a biomarker in a study of human hepatitis virus B. Hepatology research : the official journal of the Japan Society of Hepatology 54 (3) (2024)
Takehisa Watanabe, Katsuya Nagaoka
An RNA-degrading enzyme emerges as a biomarker in a study of human hepatitis virus B. Hepatology research : the official journal of the Japan Society of Hepatology 54 (3) (2024)
Takehisa Watanabe, Katsuya Nagaoka
An RNA-degrading enzyme emerges as a biomarker in a study of human hepatitis virus B. Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. Cancer medicine (2023)
Yoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Takayuki Tokunaga, Estuko Iio, Takehisa Watanabe, Hiroko Setoyama, Masakuni Tateyama, Koji Yoshida, Takuya Tsunoda, Yusuke Nakamura, Motohiko Tanaka, Yutaka Sasaki, Yasuhito Tanaka
A randomized phase I / II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. Cancer medicine (2023)
Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Kotaro Fukubayashi, Motohiko Tanaka, Yasuhito Tanaka
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers 15 (5) (2023)
Yoshihito Nagura, Takanori Suzuki, Kentaro Matsuura, Shintaro Ogawa, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Katsuya Nagaoka, Etsuko Iio, Takehisa Watanabe, Hiromi Kataoka, Yasuhito Tanaka
Serum IP-10/CXCL10 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents. Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Takehisa Watanabe, Katsuya Nagaoka
An RNA-degrading enzyme emerges as biomarker study of human hepatitis virus B. Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Kotaro Fukubayashi, Motohiko Tanaka, Yasuhito Tanaka
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers 15 (5) (2023)
Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. Cancer medicine (2023)
Yoki Furuta, Ryosuke Gushima, Hideaki Naoe, Munenori Honda, Yuiko Tsuruta, Katsuya Nagaoka, Takehisa Watanabe, Masakuni Tateyama, Nahoko Fujimoto, Shinya Hirata, Eiko Miyagawa, Komei Sakata, Yumiko Mizuhashi, Mikako Iwakura, Masayuki Murai, Masao Matsuoka, Yoshihiro Komohara, Yasuhito Tanaka
Possible Association of Mutations in the MEFV Gene with the Intestinal Phenotype of Behçet's Disease and Refractoriness to Treatment. Journal of clinical medicine 12 (9) (2023)
Yoki Furuta, Ryosuke Gushima, Hideaki Naoe, Munenori Honda, Yuiko Tsuruta, Katsuya Nagaoka, Takehisa Watanabe, Masakuni Tateyama, Nahoko Fujimoto, Shinya Hirata, Eiko Miyagawa, Komei Sakata, Yumiko Mizuhashi, Mikako Iwakura, Masayuki Murai, Masao Matsuoka, Yoshihiro Komohara, Yasuhito Tanaka
Possible Association of Mutations in the MEFV Gene with the Intestinal Phenotype of Behçet's Disease and Refractoriness to Treatment. Journal of clinical medicine 12 (9) (2023)
Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. Cancer medicine 13 (1) (2023)
Satoshi Narahara, Takehisa Watanabe, Katsuya Nagaoka, Nahoko Fujimoto, Yoki Furuta, Kentaro Tanaka, Takayuki Tokunaga, Takeshi Kawasaki, Yoko Yoshimaru, Hiroko Setoyama, Kentaro Oniki, Junji Saruwatari, Masakuni Tateyama, Hideaki Naoe, Motohiko Tanaka, Yasuhito Tanaka, Yutaka Sasaki
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma. Hepatology communications (2021)
Sanae Hayashi, Katsuya Nagaoka, Yasuhito Tanaka
Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins. International journal of molecular sciences 22 (20) (2021)